



## Treace to Present at 44th Annual J.P. Morgan Healthcare Conference

December 30, 2025

PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately 7:30 am PT.

A live webcast and replay of the fireside chat will be available on the Company's investors relations website at <https://investors.treace.com/>.

### Internet Posting of Information

Treace routinely posts information that may be important to investors in the "Investor Relations" section of its website at [www.treace.com](http://www.treace.com). The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

### About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty<sup>®</sup> 3D Bunion Correction<sup>®</sup> System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty<sup>®</sup> Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty<sup>®</sup> 3D Minimally Invasive Bunion Correction System and the Percuplasty<sup>™</sup> Percutaneous 3D Bunion Correction System and the SpeedMTP<sup>®</sup> MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate<sup>®</sup> rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide<sup>™</sup> patient specific, pre-op planning and cut guide technology. For more information, please visit [www.treace.com](http://www.treace.com).

To learn more about Treace, connect with us on [LinkedIn](#), [X](#), [Facebook](#) and [Instagram](#).

### Contacts:

#### Treace Medical Concepts

Mark L. Hair  
Chief Financial Officer  
[mhair@treace.net](mailto:mhair@treace.net)  
(904) 373-5940

#### Investors:

**Gilmartin Group**  
Philip Trip Taylor  
[IR@treace.net](mailto:IR@treace.net)